# Orion Corporation, Orion Pharma clinical trials: 101 (2026)

ClinicalTrials.gov lists 101 trials with Orion Corporation, Orion Pharma as lead sponsor, 3 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Orion Corporation, Orion Pharma: 101 rows for $5.05, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/orion-corporation-orion-pharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 101
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 101, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 4, 2026 | NCT07805252 | Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer | Orion Corporation, Orion Pharma | Phase 1/2 | Recruiting | Advanced Solid Tumors Cancer | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805252) |
| May 4, 2026 | NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 | Orion Corporation, Orion Pharma | Phase 1/2 | Recruiting | Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer) | 229 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563738) |
| May 4, 2025 | NCT06956495 | Efficacy and Tolerability of Tasipimidine in Sleepless Patients | Orion Corporation, Orion Pharma | Phase 2 | Completed | Insomnia | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956495) |
| December 10, 2024 | NCT06725758 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours | Orion Corporation, Orion Pharma | Phase 1/2 | Recruiting | Solid Tumours | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06725758) |
| April 13, 2023 | NCT05811039 | Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal | Orion Corporation, Orion Pharma | Not applicable | Completed | Itching | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05811039) |
| March 18, 2022 | NCT05288075 | Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05288075) |
| February 18, 2022 | NCT05246046 | Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy Volunteers | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05246046) |
| October 19, 2021 | NCT05084222 | Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing | Orion Corporation, Orion Pharma | Phase 4 | Completed | Asthma | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05084222) |
| May 3, 2021 | NCT04869384 | Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma | Orion Corporation, Orion Pharma | Phase 4 | Completed | Asthma | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04869384) |
| April 22, 2021 | NCT04856098 | Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy Volunteers | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04856098) |
| April 20, 2021 | NCT04850144 | Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy Volunteers | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04850144) |
| December 11, 2020 | NCT04663386 | Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway | Orion Corporation, Orion Pharma | Observational | Terminated | Asthma, COPD | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04663386) |
| October 1, 2020 | NCT04571996 | Blood-Brain Barrier Penetration of Therapeutic Agents in Human | Orion Corporation, Orion Pharma | Phase 1 | Completed | CNS Disease | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04571996) |
| January 13, 2020 | NCT04225884 | Digital Therapeutics (DTx) for Pain: Pilot Study of a Virtual Reality Software for Chronic Pain | Orion Corporation, Orion Pharma | Not applicable | Completed | Chronic Low Back Pain | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04225884) |
| November 1, 2019 | NCT04147572 | Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler | Orion Corporation, Orion Pharma | Not applicable | Completed | Healthy Volunteer, COPD | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04147572) |
| May 13, 2019 | NCT03948178 | Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension | Orion Corporation, Orion Pharma | Phase 3 | Terminated | Amyotrophic Lateral Sclerosis | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03948178) |
| May 10, 2019 | NCT03945344 | Effect of Charcoal on Gastrointestinal Absorption of Tiotropium | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy Volunteer Study | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03945344) |
| March 18, 2019 | NCT03878823 | Safety and Pharmacokinetics of ODM-209 | Orion Corporation, Orion Pharma | Phase 1/2 | Completed | Prostate Cancer Metastatic, Advanced Breast Cancer, Castration-resistant Prostate Cancer, Metastatic Breast Cancer | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03878823) |
| January 23, 2019 | NCT03813277 | Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU | Orion Corporation, Orion Pharma | Phase 4 | Completed | ICU Sedation | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03813277) |
| January 14, 2019 | NCT03802903 | Efficacy and Safety of Remo-Wax for Removal of Impacted Earwax | Orion Corporation, Orion Pharma | Not applicable | Completed | Cerumen Impaction of Both Ears | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03802903) |
| November 28, 2018 | NCT03755544 | Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD | Orion Corporation, Orion Pharma | Observational | Completed | Asthma, Chronic Obstructive Pulmonary Disease | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03755544) |
| April 20, 2018 | NCT03505021 | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | Orion Corporation, Orion Pharma | Phase 3 | Completed | Amyotrophic Lateral Sclerosis | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03505021) |
| February 19, 2018 | NCT03436485 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | Orion Corporation, Orion Pharma | Phase 1/2 | Active not recruiting | Prostate Cancer Metastatic | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03436485) |
| January 17, 2018 | NCT03400241 | Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03400241) |
| August 7, 2017 | NCT03240445 | Impact of Changing the Dosing Regimen on the PK Profile of ODM-203 | Orion Corporation, Orion Pharma | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03240445) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 49 |
| Phase 1/2 | 9 |
| Phase 2 | 13 |
| Phase 3 | 8 |
| Phase 4 | 9 |
| Not applicable | 8 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 89 |
| Terminated | 8 |
| Recruiting | 3 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Asthma | 21 |
| Parkinson Disease | 11 |
| Prostatic Neoplasms | 5 |
| Pulmonary Disease, Chronic Obstructive | 5 |
| Amyotrophic Lateral Sclerosis | 3 |
| Alzheimer Disease | 2 |
| Pain | 2 |
| Heart Diseases | 1 |
| Dermatitis, Atopic | 1 |
| Dermatitis | 1 |
| Raynaud Disease | 1 |
| Scleroderma, Systemic | 1 |
| Critical Illness | 1 |
| Coronary Disease | 1 |
| Ischemic Attack, Transient | 1 |
| Stroke | 1 |
| Central Nervous System Diseases | 1 |
| Mesothelioma | 1 |
| Pancreatic Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Heart Failure | 1 |
| Pruritus | 1 |
| Constipation | 1 |
| Sleep Initiation and Maintenance Disorders | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Suppliers and distributors in the United States](https://specstream.ai/data/businesses/suppliers-and-distributors/united-states)
- [Flight schools in the United States](https://specstream.ai/data/businesses/flight-schools/united-states)
- [Thai restaurants in the United States](https://specstream.ai/data/businesses/thai-restaurants/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
